ストックスクリーナーアプリを入手
48.06
0.93%
0.49
前日終値:
$47.57
開ける：
$47.78
24時間の取引高:
1.20M
Relative Volume:
0.09
時価総額：
$100.17B
収益：
$47.64B
当期純損益:
$5.42B
株価収益率:
18.00
EPS:
2.67
ネットキャッシュフロー:
$13.09B
1週間 パフォーマンス:
-4.36%
1か月 パフォーマンス:
-13.01%
6か月 パフォーマンス:
-12.25%
1年 パフォーマンス:
+9.02%
1日の値動き範囲:
$47.50
$48.06
1週間の範囲:
$47.40
$50.65
52週間の値動き範囲:
$39.35
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
48.06 | 100.17B | 47.64B | 5.42B | 13.09B | 2.67 |
|
LLY
Lilly Eli Co
|
777.42 | 696.19B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.75 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
187.60 | 342.31B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
68.68 | 289.25B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
111.87 | 224.07B | 53.22B | 12.86B | 14.85B | 6.39 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 開始されました | Piper Sandler | Overweight |
| 2024-12-16 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-07-10 | 開始されました | SVB Securities | Market Perform |
| 2023-06-28 | 開始されました | Daiwa Securities | Outperform |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 開始されました | Credit Suisse | Neutral |
| 2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Underweight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-01 | ダウングレード | Argus | Buy → Hold |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | アップグレード | Truist | Hold → Buy |
| 2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-07-28 | 開始されました | Raymond James | Outperform |
| 2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-06 | 再開されました | Citigroup | Buy |
| 2019-12-13 | アップグレード | Argus | Hold → Buy |
| 2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-05-20 | ダウングレード | Argus | Buy → Hold |
| 2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 再開されました | JP Morgan | Overweight |
| 2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
| 2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MSN
BMS Commits $40B over Five Years to U.S. R&D, Manufacturing - Genetic Engineering and Biotechnology News
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight - Benzinga
Bristol-Myers GC Hands Over Legal Department To Successor - Law360
Bristol Myers Squibb names new executive vice president By Investing.com - Investing.com Canada
Bristol Myers (BMY) Experiences Increased Bearish Activity in Op - GuruFocus
Bristol Myers (BMY) Unveils $40 Billion Investment in U.S. Over Five Years | BMY Stock News - GuruFocus
Bristol Myers Squibb Appoints Cari Gallman as EVP, General Counsel and Chief Policy Officer - citybiz
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
Bristol Myers (BMY) Appoints Cari Gallman as New General Counsel - GuruFocus
Bristol Myers Squibb’s injectable Opdivo formulation granted MHRA for solid tumours - PMLiVE
Bristol Myers Squibb announces $40bn US investment plan over five years - Yahoo Finance
Bristol Myers Squibb names new executive vice president - Investing.com
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer - Quantisnow
Bristol Myers to invest $40 billion in the US over 5 years | Business Information & News | FE - Westlaw Today
Bristol Myers to invest $40 billion in the US over 5 years - Reuters
Bristol Myers to invest $51.6 billion in the US over 5 years - The Straits Times
Company with deep NJ roots plans hundreds of more layoffs out of New Jersey - New Jersey 101.5
Bristol Myers to invest $40 billion in the US over 5 years, CEO says - marketscreener.com
Bristol Myers Promises $40 Billion US Investment Over Five Years - MSN
Bristol Myers Squibb Laying Off 500+ Employees From Lawrence Township Office - dailyvoice.com
Layoff Tracker: Pliant Cuts 45% of Staff To Extend Cash Runway - BioSpace
Was Jim Cramer Right About Bristol-Myers Squibb Company (BMY)? - Insider Monkey
Bristol-Myers Squibb (BMY) Faces Valuation Concerns - GuruFocus
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months - Benzinga
Are Wall Street Analysts Bullish on Bristol-Myers Stock? - MSN
Jim Cramer Says He Likes Bristol-Myers Squibb (BMY) More Than Merck Due to Schizophrenia Drug - Insider Monkey
MHRA approval for BMS’ SC Opdivo - The Pharma Letter
Bristol-Myers Squibb's (NYSE:BMY) Strong Earnings Are Of Good Quality - Yahoo Finance
BMY Gains UK Approval for Faster Nivolumab Injection | BMY Stock News - GuruFocus
Piper Sandler Raises Price Target for Bristol Myers (BMY) to $66 | BMY Stock News - GuruFocus
Bristol Myers Squibb: innovating oncology care - MSN
Analysis of Cancer Immunotherapy Technologies and Global Markets to 2029 - GlobeNewswire Inc.
Is Bristol-Myers Squibb Company (BMY) the Best Long-Term Dividend Stock to Buy According to Billionaires? - Insider Monkey
BMY: Bristol Myers' Chief Medical Officer Acquires Additional Sh - GuruFocus
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock - Yahoo Finance
Our impact - Bristol Myers Squibb
Jim Cramer is Recommending This Dividend Stock With 5% Yield for ‘Good Protection’ - Yahoo Finance
HSBC Adjusts Price Target for Bristol Myers (BMY) Amid Tariff Co - GuruFocus
Bristol-Myers Squibb (BMY) Revenue Beats, EPS Misses Estimates - GuruFocus
Top 3 Health Care Stocks That May Rocket Higher In April - Benzinga
Bristol-Myers Squibb (BMY) Advances with Robust Pipeline and Div - GuruFocus
Bristol-Myers Squibb First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
BofA lifts Bristol-Myers Squibb stock target to $56; keeps neutral By Investing.com - Investing.com South Africa
Bristol Myers (BMY) Faces Lowered Price Target Amid Growth Conce - GuruFocus
BofA lifts Bristol-Myers Squibb stock target to $56; keeps neutral - Investing.com Nigeria
Bristol-Myers Squibb Company (BMY): A Growing Dividend Stock with Low PE Ratio - MSN
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2025 Earnings Call Transcript - MSN
Bristol-Myers Squibb, Sanofi, and Merck and Co. discuss tariffs and manufacturing in quarterly financial call - BioProcess International
Decoding Bristol-Myers Squibb Co (BMY): A Strategic SWOT Insight - GuruFocus
Bristol Myers Schizophrenia Drug Cobenfy Failed in Key Study - MSN
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
0.03%
1.65%
大文字化:
|
ボリューム (24 時間):